About Us

Akhil Ravi is Chief Executive Officer (CEO) of Aurigene Pharmaceutical Services.

Before joining Aurigene Pharmaceutical Services from Dr. Reddy’s Laboratories on February 1, 2022, Akhil has served as Head of strategy for services and Active Pharmaceutical Ingredients (APIs), Head of API sales in Europe, and as plant head at one of Dr. Reddy’s manufacturing sites.

Akhil holds a B.Tech degree in Chemical engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).

Dr. Gayathri Ramaswamy is the Global Head of Discovery Services at Aurigene.

Dr. Gayathri joined us from Intergalactic Therapeutics, where she served as Vice President & Head of Drug Discovery and Disease Biology. Prior to Intergalactic, she held leadership positions at Biogen and Pfizer.

Dr. Gayathri has extensive experience in several therapeutic areas including neuroscience and ophthalmology, across different modalities such as small molecule, large molecule, and non-viral gene therapy. She is an expert in brain-lipid metabolism, apolipoprotein E and its role in Alzheimer’s disease.

Gayathri holds a PhD in Biochemistry St. Jude Children’s Research Hospital, University of Tennessee, Memphis, and completed her post-doctoral training at the Gladstone Institute of Neurological Diseases, University of California, San Francisco. She currently serves as a Scientific Advisory Board member for a lipid-biology focused start-up biotech based in Cambridge, Massachusetts.

Dr. Srividya joined us as a Global Head of CDMO drug substance business. She has over 22+ years of rich experience in process engineering, flow chemistry, continuous manufacturing, polymorph screening, crystallization process development and process analytical technologies. She has been associated with Dr. Reddy’s Laboratories, Bristol-Myers Squibb, and Unilever before joining us in 2024. She has a PhD in chemical engineering from Princeton University and a B.Tech from the Indian Institute of Technology, Madras.

Kapil Choudhury is Global Head of Sales and Business Development for Aurigene and is responsible for shaping the commercial strategy for Aurigene. Kapil has nearly two decades of experience in Strategy, R&D + Manufacturing Operations, Partnerships and Country Management across Pharma, Services and Consulting spaces.

Prior to joining Aurigene, Kapil was Global Head of Business Development, Alliance Management Portfolio and Product Management at Dr. Reddy’s. Kapil led Dr. Reddy’s global covid response team, which was responsible for bringing full spectrum of COVID solutions to India, including India’s third approved Viral Vector Platform based vaccine and a concurrent effort along with Merck to bring Molnupiravir to India. Kapil was awarded ET Business Leader of the year by world HRD congress in 2021 for his notable contributions for fighting COVID. Kapil also worked as engagement manager at IQVIA prior to joining Dr. Reddy’s.

Kapil is alumnus of prestigious Fergusson College, India and INSEAD Business School, France. Kapil is a member of Healthcare Academic advisory committee of IIM, IIT and AIIMS Jammu. Kapil also frequently mentors students at SOIL & IIFT and is passionate about youth skill development from rural and semi urban centers of India.

Dr. Roger Lias is a globally recognized expert in and advocate for the biologics CDMO marketplace. Roger started his career during market making periods with Celltech/Lonza and Diosynth before joining founding management teams at KBI Biopharma, Cytovance Biologics and Eden Biodesign. More recently Roger has served as CEO at Stelis Biopharma and at Avid Bioservices (NASDAQ:CDMO) and was instrumental in the sale of Vibalogics to Recipharm in 2022. At Aurigene Roger is responsible for all commercial functions supporting our Discovery and CDMO service offering in the biologics space. He serves in an advisory capacity in support of several industry groups and organizations.

Dr. Priyaranjan Pattanaik heads the NBE division at Aurigene Pharmaceutical Services Limited, engaged with discovery and development of large molecule drugs and critical bio-reagents. Priyaranjan is a structural biologist with ~18 years of experience in industry and academia. Priyaranjan has led many large molecule discovery collaborations with innovator pharma companies involving antibodies, ADC, mRNA and bi-specific modalities that have resulted in development and clinical candidates. Priyaranjan is passionate about new technologies and their application in accelerating progression of drug candidates from concept to clinic. As a business leader engaged with global clientele, Priyaranjan believes in a people-centric approach to successful collaborations underpinned by transparent communication, high integrity and a shared vision of bringing new therapies to patients faster and, in a cost effective way.

Priyaranjan received his Ph. D from Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bangalore. He carried out post-doctoral research in Medical School of Case Western Reserve University at Cleveland, Ohio, USA on structure based NCE discovery against bacterial antibiotic resistance.

Rajesh joins Aurigene from Dr. Reddy’s Laboratories and has over 21+ years of rich experience in the industry. Before moving to Aurigene, he was part of API commercial team and was working as a Program Manager- API Plus.

Rajesh holds Ph.D. in Pharmaceutical Technology from University College of Pharmaceutical Sciences, Kakatiya University and M. Pharm (Pharmaceutics) from BITS Pilani, Rajasthan.

Rajesh is responsible for heading the FR and D Space to ensure delivery of formulation development and technology transfer projects and achieve long term and short term organizational priorities.

Chetan received his PhD in synthetic organic chemistry from State University of New York at Buffalo and has over 20 years of experience in synthetic, process and medicinal chemistry in industries spanning across the globe. Chetan has experience in leading multi-disciplinary discovery and developmental teams that have delivered several preclinical and clinical candidates. He has experience in working with various target classes including Proteases, Kinases, NHR’s and Epigenetics. across different therapeutic areas of Oncology, Pain and Inflammation and Metabolic disorders. He has more than 30 patents and publications to his credit and is affiliated with Aurigene since April 2007.

Amit brings more than 20 years of experience in biotherapeutics, contract research, and manufacturing services. He has successfully created a range of mAb production techniques and scaled them up for commercial delivery. He has accomplished 25+ process development projects and 20+ clinical and commercial supply products and holds a Ph.D in Microbiology.